Biotech
Roche is Awarded the Distribution of Reagents in Soria for Two Million Euros
Roche will be the company to distribute reagents in Soria. According to the budget application, the amount for the supply of reagents in 2021 amounts to $505,000 (€424,000); in 2022 the price is just over one million, while in 2023 the amount rises to more than $710,000 (€596,000). Roche posted first-quarter 2021 sales of $16.286 billion (14.93 billion Swiss francs).
The Complejo Asistencial de Soria is reinforced in the field of diagnostics. The Government of Castilla y León has awarded the pharmaceutical laboratory Roche the supply, installation, leasing, and maintenance of the elements that allow the performance of analytical determinations in the biochemistry laboratory of this center for two million euros (VAT included), according to a document from the Health Service of the community, Sacyl.
The contract has a duration of 26 months from the date of award. “Taking into account that the Soria healthcare management does not have its own staff to carry out the service, it is considered necessary to contract it out to a specialized company,” reads the justification report. Roche has won this contract over Abbott, as it has submitted a better offer in terms of quality and price.
According to the budget application, the amount for the supply of reagents in 2021 amounts to $505,000 (€424,000); in 2022 the price is just over one million, while in 2023 the amount rises to more than $710,000 (€596,000).
Read more on the subject and find the most important financial news from around the world with our companion app Born2Invest.
The Complejo Asistencial de Soria is provided with reagents for the next 26 months
As regards equipment leasing, the price for 2021 is $14,976 (€12,570); for 2022, more than $44,000 (€37,000), and for 2023, $29,960 (€25,140). For maintenance, the amounts are $12,800 (€10,774), $38,516 (€32,322.4) and $25,677 (€21,548.3) in 2021, 2022, and 2023, respectively. Roche posted first-quarter 2021 sales of $16.286 billion (14.93 billion Swiss francs) versus $16.518 billion (15.143 billion Swiss francs), down 1.4%.
The drugmaker maintained sales thanks to Covid-19 diagnostic tests, which offset the drop in its main business, drugs. The Basel-based company, which does not report quarterly profit, has indicated that the strong Swiss franc reduced revenues.
The center provides healthcare coverage for the entire province of Soria and is divided into fourteen basic health zones
Sales in the diagnostics division were boosted by demand for tests of various types related to Covid-19. This division experienced a 50% rise to $4.7 billion (4.3 billion Swiss francs).
The Soria healthcare complex consists of the Santa Bárbara and Virgen del Mirón hospitals. This center provides healthcare coverage to the entire province of Soria and is divided into fourteen basic health zones: approximately 89,539 inhabitants, living in an area of 10,284 square kilometers.
__
(Featured image by Efraimstochter via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Fintech1 week ago
Pennylane and Defacto Strengthen Alliance to Facilitate Instant Payments for SMEs
-
Biotech2 days ago
Novo Nordisk Completes Acquisition of Catalent and Accelerates with Wegovy
-
Impact Investing1 week ago
Greenway Registers 11.3% Net Profit in 2024
-
Crowdfunding2 weeks ago
The 4th Edition of the Civic Crowdfunding of the Municipality of Venice Is Underway